If this message is not displayed correctly, click here.
|
|
ERA-EDTA FLASH is the official ERA-EDTA E-NEWSLETTER
No 156, September 2018
|
|
Editor in Chief: María José Soler Romeo - Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini
ERA-EDTA Headquarters - Via XXIV Maggio, 38 - 43123 Parma - Italy
|
|
|
|
A new Webinar will be held on TUESDAY, September 25, 2018 at 4:00-5:00 pm CET (3:00 pm UK time, 5:00 pm Eastern European time).
Justine Bacchetta (University Hospital Lyon) will present on ‘CKD-MBD – pathophysiology and management'.
Register here, to receive the access link to the Webinar.
Please pay attention to the technical requirements provided with the access link.
If you would like to be notified automatically about future Rare Kidney Disease Webinars, please sign up here for the ERKNet Newsletter.
You can find the schedule for upcoming Webinars and past presentations at www.erknet.org under the ‘Education & Training’ tab.
|
|
During the 55th ERA-EDTA Congress 2018 in Copenhagen, the following two industry symposia about CKD-MBD supported by Vifor Fresenius Medical Care Renal Pharma and AstraZeneca Pharmaceuticals were presented:
- Controversies surrounding RAASi treatment and hyperkalaemia in cardio-renal patients (Supported by Vifor Fresenius Medical Care Renal Pharma)
Topics: “Pathophysiology of recurrent hyperkalaemia”, “RAASi benefits in slowing down kidney function decline” and “New treatment options in hyperkalaemia management”. Find the webcasts and available presentations on the ENP here. - Innovations in CKD: Can K+ Binders and HIF Stabilisers Improve Mr Andersen’s Life? (Supported by AstraZeneca Pharmaceuticals)
Topics: “Chair's introduction: Let's Meet Mr Andersen”, “Is there new hope for managing Mr Andersen’s hyperkalaemia?”, “Can we treat Mr Andersen’s anaemia without increasing cardiovascular risk?” and “Will these innovations improve Mr Andersen’s and other patients’ lives?”. Find the webcasts on the ENP here.
You can find all available industry symposia in addition to other topics on the ENP here.
|
|
Calcium oxalate (CaOx) deposition is an under-recognised cause of impaired kidney function. Palsson et al. report that CaOx deposition is both common after kidney transplantation and associated with adverse outcomes (DGF, graft failure and death). The paper is accessible here free of charge until this Sunday at 23.59 (UK time).
Do not miss it!
|
|
Click here to download it.
|
|
Aren’t you an ERA-EDTA member yet? Click here to become one.
|
|
|
|
|
|
|
|
|
|
|
|
|
Initiatives
|
|
Working Groups
...and their latest initiatives:
|
|
Committees...
...and their main newsletters:
|
|
|
|
The advantages of being a member of ERA-EDTA
As a member you will become part of one of the
most influential European Medical Associations!
|
|
The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003.